MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Recruiting
Observational Study
Autoimmune Liver Disease
Primary Sclerosing Cholangitis
Autoimmune Hepatitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 6 – 23
- Sex
- Any
- Study type
- Observational
- Participants needed
- 115 (estimated)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age 6-23 years old.
2. Established or suspected clinical diagnosis of AIH or PSC.
Exclusion Criteria:
1. History of liver transplantation.
2. Chronic Hepatitis B or untreated hepatitis C virus infection.
3. Pregnancy.
4. Absolute contraindication for MRI (e.g. pacemaker, me…
Contacts